All In Biotech

Drug Trial Radar · NCT07894211

QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

A Randomized, Open-Label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of QLC5508 Versus Investigator's Choice Chemotherapy in Participants With Advanced Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) That Has Failed After Platinum-Containing Chemotherapy

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Mar 26, 2029

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 versus investigator's choice chemotherapy in participants with advanced EP-NEC that has failed after at least one prior platinum-based chemotherapy regimen.

Conditions

  • Extrapulmonary Neuroendocrine Carcinoma

Interventions

  • Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen)Drug

    FOLFIRI regimen: Irinotecan 180 mg/m² intravenous infusion on Day 1 and Day 15, leucovorin 400 mg/m² intravenous infusion on Day 1 and Day 15, and fluorouracil 400 mg/m² intravenous push on Day 1 and Day 15, followed by fluorouracil 2400 mg/m² via continuous intravenous infusion over 46-48 hours, once every 2 weeks. Each treatment cycle is 4 weeks. FOLFOX regimen: oxaliplatin 85 mg/m² intravenous infusion on Day 1 and Day 15, leucovorin 400 mg/m² intravenous infusion on Day 1 and Day 15, and fluorouracil 400 mg/m² intravenous push on Day 1 and Day 15, followed by fluorouracil 2400 mg/m² via continuous intravenous infusion over 46-48 hours, once every 2 weeks. Each treatment cycle is 4 weeks.

  • QLC5508Drug

    QLC5508 will be administered intravenously once every 2 weeks. Each treatment cycle is 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to approximately 48 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.